StreetAlpha.app
Home › Stocks › SGMT

Sagimet Biosciences Inc. (SGMT)

Healthcare
$9.85
▼ −2.76%
LAST CLOSE · NOV 17

Sagimet Biosciences develops FASN inhibitor drugs, led by denifanstat, for liver disease, acne and certain cancers. It last closed at $9.85 on Nov 17, down 2.76% on the day. The average 12-month price target from 8 analysts is $25.71 (+161.1% from the last close), with a high of $50.00 and a low of $7.00. Analyst consensus is Buy, based on the latest ratings from 8 firms (7 buy, 0 hold, 1 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in SGMT, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is SGMT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$53.3M
EPS (diluted)
−$1.18
Balance sheet
Cash & equivalents
$111.0M
At Sep 30
Shareholder equity
$242.2M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$30.5M−$30.5MFY2022FY2023: −$27.9M−$27.9MFY2023FY2024: −$45.6M−$45.6MFY2024FY2025: −$51.0M−$51.0MFY2025

From SGMT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 8 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
8firms
7 Buy0 Hold1 Sell
Each firm's latest rating on SGMT in the past 90 days
Average 12-month target
$25.71
▲ 161.1% upside

Based on 8 analysts who set a price target on SGMT in the past 90 days. The average target is $25.71, with a high of $50.00 and a low of $7.00, compared with the last close of $9.85.

Low $7.00Avg $25.71High $50.00
Blue marker: last close $9.85
Highest target$50.00
Average target$25.71
Lowest target$7.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 13Buy$56 → $50
GuggenheimMaintained
Oct 2Buy$26
OppenheimerMaintained
Oct 1Buy$38
CitizensTarget lowered
Oct 1Buy$29 → $27
Goldman SachsReinstated
Sep 24Sell$7
DateFirmActionRatingPrice target
Nov 13Canaccord GenuityTarget loweredBuy$56 → $50
Oct 2GuggenheimMaintainedBuy$26
Oct 1OppenheimerMaintainedBuy$38
Oct 1CitizensTarget loweredBuy$29 → $27
Sep 24Goldman SachsReinstatedSell$7
Loading…

Technical Analysis

SGMT · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 21% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $9.60, and the nearest resistance the Pivot at $9.89.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$11.4552 week high+16.2%
$10.21Swing high (Oct 21)+3.7%
$10.1720 day average+3.2%
$10.14Pivot R1+2.9%
$9.89Pivot+0.4%
$9.8550 day average+0.0%
$9.85Last close
$9.60Pivot S1−2.5%
$9.41Swing low (Oct 26)−4.5%
$9.29100 day average−5.7%
$7.75200 day average−21.3%
$4.5052 week low−54.3%
Indicators
RSI (14)48.56Middle of its rangeNeutral
MACD0.22Below its signal lineBearish
Stochastic43.3Middle of its rangeNeutral
ADX (14)19.2No clear trend
Williams %R-65.7Oversold below −80, overbought above −20Neutral
CCI (20)-44.8Oversold below −100, overbought above 100Neutral
Rate of change−1.0%Change over 10 sessionsBearish
ATR (14)$0.66Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for SGMT

What happened before

See how SGMT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SGMT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SGMT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Oct 5 – Oct 5
Loading…

See today’s whale options flow across the market →

SGMT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 43 selling
  • ▲Shares held by funds +36.7%
  • ▲Funds holding +32
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding154122+26.2%
In funds' top 1030–
Held by funds–––
New / increased50 / 5757 / 37+13.8%
Reduced / sold out23 / 209 / 24+30.3%
Put/call ratio11.31––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SGMT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGMT is in one of them and how their past SGMT trades turned out.

SGMT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SGMT in an article yet. Here's the latest on the wider market.

About Sagimet Biosciences

Sagimet Biosciences is a biopharmaceutical company based in Foster City, California, that develops drugs called FASN inhibitors. Its lead candidate, denifanstat, is a pill taken by mouth once a day that is being studied for MASH, a serious form of fatty liver disease, along with acne and certain cancers. A second candidate, TVB-3567, is in early human testing for acne. The company aims these medicines at patients with metabolic and liver conditions, and a licensee in China is developing denifanstat for acne.

Headquarters
Foster City, CA